Association of clonal hematopoiesis of indeterminate potential with cardiovascular mortality in cardiovascular-kidney-metabolic syndrome: a large prospective cohort study.
- 1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- 2National Clinical Research Center For Cardiovascular Disease, Beijing, China.
- 3Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Abstract
Background
Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive pathophysiological continuum. While clonal hematopoiesis of indeterminate potential (CHIP) is known to increase the risk of CKM disease onset and adverse prognoses, its overall and stage-specific impacts on cardiovascular mortality within the CKM framework, alongside the circulating proteomic mechanisms mediating this excess risk, remain largely unknown.Methods
Participants from the UK Biobank with available CHIP data across the CKM syndrome continuum were included. The primary outcome was cardiovascular mortality. Kaplan-Meier curves and multivariable Cox proportional hazards models were utilized to evaluate the incremental risk conferred by CHIP. Sensitivity and subgroup analyses were conducted to ascertain result robustness. Within UKB Pharma Proteomics Project (UKB-PPP), circulating proteins jointly associated with CHIP and cardiovascular mortality were identified, followed by functional enrichment and mediation analyses to elucidate the underlying mechanisms.Results
During a median follow-up of 16.5 years, 6,515 cardiovascular deaths were recorded among 288,384 participants across CKM stages 1-4. Across all varying CKM stages, individuals harboring Large CHIP exhibited a significantly higher risk of cardiovascular mortality compared to the non-CHIP group (all log-rank P < 0.05). Following multivariable adjustment, Large CHIP emerged as an independent risk factor for cardiovascular mortality (hazard ratio, 1.24; 95% confidence interval, 1.09-1.40), with subgroup analyses confirming consistent effects regardless of CKM stage or established cardiometabolic and renal diseases. Proteomic profiling, corroborated by UKB-PPP, revealed that the mechanisms driving this excess risk predominantly involve immune-inflammatory dysregulation and tissue structural remodeling. This pathway was highlighted by critical downstream mediators, including the structural component DSC2 (mediating 34.3% of the risk) and key immune-regulatory receptors such as VSIG4 (33.1%) and CD300C (29.2%).Conclusions
CHIP is an independent risk factor for cardiovascular mortality across all stages of CKM syndrome. Mechanistically, CHIP exacerbates this adverse outcome primarily by driving systemic inflammation, immune dysregulation, and aberrant tissue remodeling.
Related
- Clonal Hematopoiesis of Indeterminate Potential and Bone Mineral Density in Cohorts from Trans-Omics for Precision Medicine
- Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy
- Effect of clonal hematopoiesis of indeterminate potential on long-term survival in patients with arrhythmias
- Association of sleep time with all-cause and cardiovascular mortality among individuals with advanced cardiovascular-kidney-metabolic syndrome : A NHANES-based prospective cohort study
- Association of 24 h Pulse Pressure Derived from Ambulatory Blood Pressure Monitoring with All-Cause and Cardiovascular Mortality in Patients Undergoing Peritoneal Dialysis: A Prospective Cohort Study
BibTeX
@article{zhao2026association,
title = {{Association of clonal hematopoiesis of indeterminate potential with cardiovascular mortality in cardiovascular-kidney-metabolic syndrome: a large prospective cohort study.}},
author = {Zehao Zhao and Changsheng Ma and Libo Zhao and Xiliang Zhao and Quan Li and Yaodong Ding and Yang Zhang and Li Lin and Wenjie Wang and Jiayi Han and Yingxuan Bai and Tianyi Wang and Yong Zeng},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1910361},
url = {https://europepmc.org/article/MED/42909319},
note = {CC BY},
}
RIS
TY - JOUR
TI - Association of clonal hematopoiesis of indeterminate potential with cardiovascular mortality in cardiovascular-kidney-metabolic syndrome: a large prospective cohort study.
AU - Zehao Zhao
AU - Changsheng Ma
AU - Libo Zhao
AU - Xiliang Zhao
AU - Quan Li
AU - Yaodong Ding
AU - Yang Zhang
AU - Li Lin
AU - Wenjie Wang
AU - Jiayi Han
AU - Yingxuan Bai
AU - Tianyi Wang
AU - Yong Zeng
PY - 2026
DA - 2026/10/07
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1910361
UR - https://europepmc.org/article/MED/42909319
AB - Background Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive pathophysiological continuum. While clonal hematopoiesis of indeterminate potential (CHIP) is known to increase the risk of CKM disease onset and adverse prognoses, its overall and stage-specific impacts on cardiovascular mortality within the CKM framework, alongside the circulating proteomic mechanisms mediating this excess risk, remain largely unknown.Methods Participants from the UK Biobank with available CHIP data across the CKM syndrome continuum were included. The primary outcome was cardiovascular mortality. Kaplan-Meier curves and multivariable Cox proportional hazards models were utilized to evaluate the incremental risk conferred by CHIP. Sensitivity and subgroup analyses were conducted to ascertain result robustness. Within UKB Pharma Proteomics Project (UKB-PPP), circulating proteins jointly associated with CHIP and cardiovascular mortality were identified, followed by functional enrichment and mediation analyses to elucidate the underlying mechanisms.Results During a median follow-up of 16.5 years, 6,515 cardiovascular deaths were recorded among 288,384 participants across CKM stages 1-4. Across all varying CKM stages, individuals harboring Large CHIP exhibited a significantly higher risk of cardiovascular mortality compared to the non-CHIP group (all log-rank P < 0.05). Following multivariable adjustment, Large CHIP emerged as an independent risk factor for cardiovascular mortality (hazard ratio, 1.24; 95% confidence interval, 1.09-1.40), with subgroup analyses confirming consistent effects regardless of CKM stage or established cardiometabolic and renal diseases. Proteomic profiling, corroborated by UKB-PPP, revealed that the mechanisms driving this excess risk predominantly involve immune-inflammatory dysregulation and tissue structural remodeling. This pathway was highlighted by critical downstream mediators, including the structural component DSC2 (mediating 34.3% of the risk) and key immune-regulatory receptors such as VSIG4 (33.1%) and CD300C (29.2%).Conclusions CHIP is an independent risk factor for cardiovascular mortality across all stages of CKM syndrome. Mechanistically, CHIP exacerbates this adverse outcome primarily by driving systemic inflammation, immune dysregulation, and aberrant tissue remodeling.
SN - 1664-2392
ER -